Quinoline-based derivatives of pirinixic acid as dual PPAR α/γ agonists

Archiv der Pharmazie

Volumn 340, Issue 7, 2007, Pages 367-371

  Popescu, Laura ^a   Rau, Oliver ^a   Böttcher, Jark ^b   Syha, Yvonne ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

dual agonist; Peroxisome proliferator activated receptor; Pirinixic acid; PPAR

Indexed keywords

2 [4 CHLORO 6 (QUINOLIN 6 YLAMINO) PYRIMIDIN 2 YLSULFANYL]HEXANOIC ACID; 2 [4 CHLORO 6 (QUINOLIN 6 YLAMINO) PYRIMIDIN 2 YLSULFANYL]OCTANOIC ACID; 2 [4 CHLORO 6 (QUINOLIN 6 YLAMINO) PYRIMIDIN 2 YLSULFANYL]PROPIONIC ACID; 2 [4 CHLORO 6 (QUINOLIN 6 YLOXY) PYRIMIDIN 2 YLSULFANYL]OCTANOIC ACID; 2 [4 CHLORO 6 [(QUINOLIN 6 YLMETHYL) AMINO] PYRIMIDIN 2 YLSULFANYL]OCTANOIC ACID; 2 [5 [3,5 BIS (2,2,2 TRIFLUORO ETHOXY) PHENYLAMINO] 4 CHLORO PYRIMIDIN 2 YLSULFANYL]OCTANOIC ACID; [4 CHLORO 6 (QUINOLIN 6 YLAMINO) PYRIMIDIN 2 YLSULFANYL]ACETIC ACID; [4 CHLORO 6 (QUINOLIN 6 YLOXY) PYRIMIDIN 2 YLSULFANYL]ACETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; QUINOLINE DERIVATIVE; TESAGLITAZAR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; PRIORITY JOURNAL; REPORTER GENE;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GENES, REPORTER; LUCIFERASES; MODELS, MOLECULAR; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; QUINOLINES;

EID: 34547206605     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700042     Document Type: Article

References (19)

1. B. Desvergne, W. Wahli, Endocr Rev 1999, 20, 649-688.
2. T. M. Willson, P. J. Brown, D. D. Sternbach, B. R. Henke, J. Med. Chem. 2000, 43, 527-550.
3. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, C. K. Glass, Nature 1998, 391, 79-82.
4. C. Jiang, A. T. Ting, B. Seed, Nature 1998, 391, 82-86.
5. A. Castrillo, P. Tontonoz, Annu Rev Cell Dev Biol 2004, 20, 455-480.
6. R. Genolet, W. Wahli, L. Michalik, Curr Drug Targets Inflamm Allergy 2004, 3, 361-375.
7. M. Lehrke, M. A. Lazar, Nat Med 2004, 10, 126-127.
8. A. A. Santilli, A. C. Scotese, R. M. Tomarelli, Experientia 1974, 30, 1110-1111.
9. J. K. Reddy, D. E. Moody, D. L. Azarnoff, R. M. Tomarelli, Int Pharmacodyn Ther 1977, 225, 51-57.
10. I. Issemann, S. Green, Nature 1990, 347, 645-650.
11. S. A. Kliewer, B. M. Forman, B. Blumberg, E. S. Ong, et al., Proc Natl Acad Sci USA 1994, 91, 7355-7359.
12. S. Derksen, O. Rau, P. Schneider, M. Schubert-Zsilavecz, G. Schneider, Chem Med Chem 2006, 1, 1346-1350.
13. O. Rau, M. Wurglics, T. Dingermann, M. Abdel-Tawab, M. Schubert-Zsilavecz, Pharmazie 2006, 61, 952-956.
14. O. Rau, M. Wurglics, A. Paulke, J. Zitzkowski, et al., Planta Med 2006, 72, 881-887.
15. S. Ulrich, S. M. Loitsch, O. Rau, A. von Knethen, et al., Cancer Res 2006, 66, 7348-7354.
16. G. d'Atri, P. Gomarasca, G. Resnati, G. Tronconi, et al., J. Med Chem 1984, 27, 1621-1629.
17. M. Rarey, B. Kramer, T. Lengauer, G. Klebe, J Mol Biol 1996, 261, 470-489.
18. S. A. Hindle, M. Rarey, C. Buning, T. Lengaue, J Comput Aided Mol Des 2002, 16, 129-149.
19. P. Cronet, J. F. Petersen, R. Folmer, N. Blomberg, et al., Structure (Camb) 2001, 9, 699-706.